E
Oncolytics Biotech Inc. ONC.TO
TSX
Recommendation
Prev Close
$1.42
Volume
--
Avg Vol (90D)
61,594
Market Cap
$93.41M
Dividend & Yield
--
52-Week Range
$0.45 - $1.85
P/E (TTM)
--
EPS (TTM)
-$0.28
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Franklin Resources Inc. Purchases Shares of 16,254 BeOne Medicines Ltd. - Sponsored ADR $ONC
12/3/2025 - MarketBeat
Daiwa Reaffirms Their Buy Rating on BeiGene Ltd (6160)
12/3/2025 - TipRanks Financial Blog
BeOne Medicines (NASDAQ:ONC) Director Corazon (Corsee) Sanders Sells 2,627 Shares
12/2/2025 - MarketBeat
Virtus Investment Advisers LLC Invests $389,000 in BeOne Medicines Ltd. - Sponsored ADR $ONC
12/1/2025 - MarketBeat
Legal & General Group Plc Buys Shares of 57,243 BeOne Medicines Ltd. - Sponsored ADR $ONC
12/1/2025 - MarketBeat
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20?
11/30/2025 - Insider Monkey
PNC Financial Services Group Inc. Makes New $228,000 Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC
11/29/2025 - MarketBeat
Edmond DE Rothschild Holding S.A. Invests $9.93 Million in BeOne Medicines Ltd. - Sponsored ADR $ONC
11/27/2025 - MarketBeat
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
11/26/2025 - Business Wire
BeOne Medicines (NASDAQ:ONC) Shares Down 4.5% - Should You Sell?
11/26/2025 - MarketBeat
Truist Financial Begins Coverage on BeOne Medicines (NASDAQ:ONC)
11/25/2025 - MarketBeat
Xiaobin Wu Sells 3,991 Shares of BeOne Medicines (NASDAQ:ONC) Stock
11/20/2025 - MarketBeat
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
11/20/2025 - Business Wire
Royal Bank Of Canada Increases BeOne Medicines (NASDAQ:ONC) Price Target to $408.00
11/19/2025 - MarketBeat
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
11/18/2025 - Zacks Investment Research
Positive Phase 3 Results Support ZIIHERA as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
11/17/2025 - Business Wire
BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 996 Shares
11/16/2025 - MarketBeat
BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 6,009 Shares
11/16/2025 - MarketBeat
BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 10,000 Shares of Stock
11/16/2025 - MarketBeat
Fiera Capital Corp Invests $5.06 Million in BeOne Medicines Ltd. - Sponsored ADR $ONC
11/16/2025 - MarketBeat
Xiaobin Wu Sells 6,009 Shares of BeOne Medicines (NASDAQ:ONC) Stock
11/15/2025 - MarketBeat
Montag A & Associates Inc. Acquires New Stake in BeOne Medicines Ltd. - Sponsored ADR $ONC
11/14/2025 - MarketBeat
We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve
11/14/2025 - Simply Wall St
BeOne Medicines (NASDAQ:ONC) Reaches New 52-Week High - Here's What Happened
11/13/2025 - MarketBeat
1,839 Shares in BeOne Medicines Ltd. - Sponsored ADR $ONC Purchased by Vestmark Advisory Solutions Inc.
11/13/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$25.02M
EBIT (TTM)
-$25.08M
Net Income (TTM)
-$25.30M
Balance Sheet
Total Assets (Q)
$10.81M
Total Debt (Q)
$599.50K
Total Liabilities (Q)
$10.73M
Book Value Per Share (Q)
$0.0008
Cash Flow
Cash from Operations (TTM)
-$18.92M
Cash from Investing (TTM)
-$9.40K
Cash from Financing (TTM)
$13.38M
Net Change in Cash (TTM)
-$5.20M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 2 and 6 (est)
Price History
Loading...
Beta
-0.34
7-Day Total Return
0.00%
30-Day Total Return
0.00%
60-Day Total Return
0.00%
90-Day Total Return
-5.96%
Year to Date Total Return
7.58%
1-Year Total Return
12.70%
2-Year Total Return
-24.87%
3-Year Total Return
-46.21%
5-Year Total Return
-69.13%
52-week Low
Jun 06, 2025 - $0.45
52-week High
Jul 17, 2025 - $1.85
Valuation
Market Cap
$93.41M - Micro Cap
Enterprise Value
$85.14M
Price/Sales (TTM)
--
Price/Book (Q)
1,775.00
Dividends and Shares
Shares Outstanding
101.32
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
oncolyticsbiotech.com
Phone Number
403 670 7377
Address
322 11th Avenue SW
Calgary, AB T2R 0C5
Country
Canada
Year Founded
1998
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an... more